Hedge funds circle Woodford’s investment trust
Patient Capital Trust is most bet-against investment trust in FTSE 350
Theravance Biopharma Ireland agrees potential $1bn deal
The company, whose parent is listed on the Nasdaq, to do study on Crohn’s disease
Soundings from China boost global markets
European shares head for longest winning streak since Chinese devaluation
Elan loses shareholder support but Royalty bid may also perish
Outcome of special meeting in Dublin leaves sides effectively in stalemate
Stalemate for Royalty Pharma’s bid for Elan as shareholders approve buyback programme
US pharma firm invited to bring forward “a new offer” following egm
Royalty Pharma co-founder writes open letter to board of Elan ahead of egm
Elan shareholders will today vote on a series of acquisitions
Elan shareholders mull the unravelling of a business
How the Irish biotech firm got to this point and how the EGM may play out
Royalty gets injunction in challenge to Takeover Panel on Elan bid
Court move means bid will not lapse pending full hearing even if shareholders back certain resolutions
Failure of Royalty Pharma bid likely to hit Elan share price, say analysts
Fate of $6.7bn offer will be decided by shareholders at extraordinary general meeting on Monday
Much noise, little clarity as Royalty and Elan go to war
Cantillon: Shareholders at Elan must be nonplussed by the frantic claim and counterclaim
Elan urges shareholders to “protect the value of their investment”
Pharmaceutical firm continues to urge shareholders to reject Royalty Pharma offer on grounds it is “grossly inadequate”
Elan drops NY lawsuit and rejects latest Royalty Pharma bid
Bidder calls on shareholders to reject all defensive acquisitions at upcoming EGM
Elan battle intensifies as Royalty Pharma raises offer by 5 per cent
Tysabri manufacturer’s shares rise 5.3 per cent
Elan wins court order to temporarily block take-over attempt
New York judge has issued a temporary restraining order blocking Royalty Pharma from “consummating or closing defendants’ tender offer” for outstanding shares in Elan
Elan says it has ‘Plan B’ if shareholders reject deals
Royalty Pharma last week increased hostile cash bid for Elan
Cantillon: Hyperactive Elan betting that it can hold shareholders
Drugmaker seems a long way from the measured approach that has typified the tenure of Kelly Martin
Royalty ups Elan bid by 10%
Irish drugmaker announces two more deals plus plans to raise $800 million
Elan to pay $1bn for Theravance stake
Irish pharmaceutical company agrees to buy 21% of royalty Theravance receives from GSK
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices